UNSPSC 51162703: Amidephrine

This classification denotes a decongestant and an alpha-adrenergic agonist with the molecular formula C10H16N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7E2P22546V, chemically known as 3-(1-hydroxy-2-(methylamino)ethyl)methanesulfonanilide, but more generally known as amidephrine, which bears US NIH Compound Identifier 15010. As of Q4 2014, AMIDEPHRINE remains US FDA's Preferred Term for this commodity. Amidephrine bears US NLM identifiers UMLS ID C0051584 and NCI Concept Code C79522. SMILES: CNCC(C1=CC(=CC=C1)NS(=O)(=O)C)O.

UNSPSC 51162703 Amidephrine is a Commodity code that encompasses pharmaceuticals and related health products procured by state and local government health departments, emergency services, and cooperative purchasing alliances. Recent solicitations show state and local buyers acquiring naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals through competitive bidding and cooperative purchasing vehicles. The buying organizations include county health departments, state pharmaceutical procurement offices, and multistate cooperative alliances that aggregate purchasing power across participating state and local members. Vendors typically supply products through authorized pharmaceutical wholesalers and must meet FDA compliance requirements, Drug Supply Chain Security Act (DSCSA) certification, current Good Manufacturing Practices (cGMP) standards, and maintain appropriate insurance coverage including commercial general liability and professional liability. Most contracts involve fixed-fee or competitive pricing structures with multi-year terms and optional renewal periods.

The code sees recent activity concentrated in Florida and Minnesota, with broader multistate participation through cooperative purchasing arrangements. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2023; the Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. MMCAP awards typically involve multi-award or sole-award decisions based on therapeutic considerations and product availability, with vendors paying a three percent administrative fee and potential performance penalties ranging from $200 to $1,500 per violation.